T-Therapeutics Ltd
Warren Hazelton is a Scientist I at T-Therapeutics Ltd, specializing in preclinical development since November 2023. Prior experience includes a role as a Postdoctoral Researcher at University College London from September 2018 to November 2023, where Warren advanced a multi-antigen targeting CAR T-cell therapy for acute myeloid leukaemia (AML) leading to successful funding applications totaling £3M. Warren's academic background includes a Doctoral study focused on the development of multi-antigen targeting chimeric antigens for AML treatment. Previous positions include Research Associate at Autolus Ltd., Research Assistant at University College London, and Industrial Placement Student at GSK, where expertise in synthetic biology, molecular biology, and tissue culture techniques was developed. Warren holds an MBiolSci degree in Biochemistry and Microbiology from The University of Sheffield.
This person is not in the org chart
T-Therapeutics Ltd
T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development. T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.